SCHEMBL5871407

SCHEMBL5871407

FC(Cc1ccccc1)N1CCC(N2CCc3ccc(Br)cc32)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
NFKB1 P19838 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
HIF1A Q16665 1/20 0.37
OPRM1 P35372 2/20 0.37
OPRD1 P41143 1/20 0.37
OPRK1 P41145 1/20 0.37
OPRL1 P41146 1/20 0.37
XIAP P98170 1/20 0.36
KCNH2 Q12809 2/20 0.35
MBTD1 Q05BQ5 1/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
SCD O00767 4/20 0.35
LMNA P02545 1/20 0.34
PMP22 Q01453 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5871303 0.90 SCD (0.42) CYP1A2CYP3A4CYP2D6NFKB1HTR2A
SCHEMBL5872031 0.86 OPRM1 (0.49) HTR2CHTR2BOPRM1OPRD1OPRK1
SCHEMBL5871656 0.86 SCD (0.44) OPRM1OPRD1OPRK1OPRL1SCD
SCHEMBL5871271 0.86 SCD (0.36) HTR2CHTR2BOPRM1OPRD1OPRK1
SCHEMBL5871811 0.85 DRD2 (0.38) OPRM1OPRD1OPRK1OPRL1KCNH2
SCHEMBL5871580 0.83 SLC22A12 (0.43) SCDHTR1AHTR1DHTR1BHTR1F
SCHEMBL5871810 0.83 SCD (0.35) HTR2CHTR2BOPRM1OPRD1OPRK1
SCHEMBL5871503 0.80 MBTD1 (0.48) OPRM1OPRK1OPRL1MBTD1L3MBTL3
SCHEMBL4076985 0.79 OGA (0.40) OPRL1LMNAHTR1AHTR1DHTR1B
SCHEMBL5871794 0.78 OPRM1 (0.46) HTR2CHTR2BOPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB CYP1A2 2772/4885CYP3A4 2377/4885CYP2D6 3306/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 CYP1A2 1842/4885CYP3A4 1529/4885CYP2D6 2709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.